Allurion Technologies (ALUR) AI Stock Analysis

• Market Cap: $14.91M
• Dividend Yield: N/A
• Average Volume (3M): 327.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.60
• Revenue Growth: -50.49%
• EPS Growth: 39.93%
• Country: US
• Employees: 134
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -1.53
• Shares Outstanding: 9,262,586
• 10 Day Avg. Volume: 176,061
• 30 Day Avg. Volume: 327,153
• PEG Ratio: 0.01
• Price to Book (P/B): -0.31
• Price to Sales (P/S): 0.75
• P/FCF Ratio: -0.56
• Enterprise Value/Market Cap: 2.89
• Enterprise Value/Revenue: 2.51
• Enterprise Value/Gross Profit: 4.11
• Enterprise Value/Ebitda: -1.29
• 1Y Price Target: $6.00
• Price Target Upside: 376.19% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -4.04
• Revenue Forecast (FY): $14.37M

• Rating: 40 Underperform
• Price Target: $1.50 ▲(19.05% Upside)

Allurion Technologies' overall stock score is primarily impacted by its poor financial performance and weak valuation metrics. Despite some positive developments in FDA approval and restructuring efforts, the company's financial instability and bearish technical indicators weigh heavily on its score.

Positive Factors

FDA Approval Progress

Achieving FDA approval milestones enhances Allurion's market potential in the U.S., providing a significant competitive advantage and growth opportunity.

Debt Restructuring

Debt restructuring strengthens Allurion's financial position, reducing leverage and interest burdens, which supports long-term financial stability.

Innovative R&D Initiatives

R&D advancements like the drug-eluting balloon can revolutionize obesity treatment, enhancing Allurion's product offerings and market position.

Negative Factors

Revenue Decline

The significant revenue decline indicates challenges in maintaining market share and sales growth, impacting long-term financial health.

Negative Cash Flows

Ongoing negative cash flows suggest liquidity constraints, limiting Allurion's ability to invest in growth and innovation without external financing.

High Leverage

High leverage increases financial risk, potentially limiting Allurion's operational flexibility and increasing vulnerability to economic downturns.

Allurion Technologies Business Overview & Revenue Model

Company Description

Allurion Technologies (ALUR) is a medical technology company focused on developing innovative solutions for weight management and obesity treatment. The company operates primarily in the healthcare sector, offering a range of products aimed at helping individuals achieve sustainable weight loss. Its core product, the Allurion Balloon, is an intragastric balloon that aids in weight loss by promoting a feeling of fullness, and is part of a comprehensive program that includes lifestyle coaching and nutritional support.

How the Company Makes Money

Allurion Technologies generates revenue through the sale of its medical devices, particularly the Allurion Balloon and associated services. The company typically sells its products directly to healthcare providers, hospitals, and clinics, which then offer these solutions to patients seeking weight loss options. Additionally, Allurion has developed partnerships with healthcare institutions and professionals to enhance the distribution of its products and services, creating a network that expands its market reach. The company may also generate income through subscription services for ongoing support and coaching, contributing to a recurring revenue model. Furthermore, Allurion's collaborations with insurance companies can facilitate reimbursement for its products, enhancing access to patients and driving sales.

Allurion Technologies Financial Statement Overview

Summary

Allurion Technologies faces significant financial challenges, including declining revenue, persistent losses, high leverage, and negative cash flows. Strategic changes are necessary to stabilize and improve financial health in a highly competitive medical devices industry.

Income Statement

Allurion Technologies has experienced significant revenue fluctuations, with a notable decline from 2022 to 2023. The company faces negative profit margins, including a negative gross profit margin in 2024, and sustained losses in net income, EBIT, and EBITDA, indicating ongoing challenges in achieving profitability.

Balance Sheet

The balance sheet reveals a concerning financial structure, with negative stockholders' equity and high leverage as indicated by a high debt-to-equity ratio. The equity ratio is negative, reflecting a risk of insolvency, compounded by the decline in assets and insufficient equity to cover liabilities.

Cash Flow

Cash flow analysis shows persistently negative operating and free cash flows, signaling liquidity issues. The company has relied heavily on financing activities to fund operations, which is unsustainable in the long term without improved financial performance.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.21M	32.11M	53.47M	64.21M	38.24M	0.00
Gross Profit	10.49M	21.50M	41.50M	50.73M	29.19M	0.00
EBITDA	-33.37M	-22.17M	-69.03M	-32.28M	-8.01M	201.13K
Net Income	-43.29M	-26.15M	-80.61M	-37.74M	-12.39M	-5.17K
Balance Sheet
Total Assets	18.14M	32.81M	71.71M	51.37M	39.35M	329.96K
Cash, Cash Equivalents and Short-Term Investments	6.14M	15.38M	38.04M	7.68M	25.84M	47.09K
Total Debt	33.39M	37.92M	41.86M	59.53M	26.14M	170.00K
Total Liabilities	101.07M	110.79M	142.20M	83.68M	73.64M	310.13K
Stockholders Equity	-82.93M	-77.98M	-70.49M	-32.31M	-34.28M	19.83K
Cash Flow
Free Cash Flow	-36.90M	-42.91M	-65.59M	-48.53M	-15.24M	-40.00
Operating Cash Flow	-36.90M	-42.30M	-63.98M	-46.98M	-14.33M	―
Investing Cash Flow	0.00	-611.00K	-1.61M	-1.55M	-912.00K	0.00
Financing Cash Flow	14.32M	20.21M	95.99M	30.54M	28.95M	47.13K

Allurion Technologies Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALUR, the sentiment is Neutral. The current price of 1.26 is below the 20-day moving average (MA) of 1.53, below the 50-day MA of 1.83, and below the 200-day MA of 2.49, indicating a neutral trend. The MACD of -0.14 indicates Negative momentum. The RSI at 50.57 is Neutral, neither overbought nor oversold. The STOCH value of 52.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ALUR.

Allurion Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVNO	58 Neutral	$13.14M	-0.57	-57.19%	―	―	18.94%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SINT	45 Neutral	$11.83M	-0.31	-204.04%	―	-60.89%	94.49%
CODX	42 Neutral	$22.73M	-0.39	-62.12%	―	-87.84%	29.16%
IRIX	41 Neutral	$17.67M	-3.18	-139.29%	―	4.58%	55.26%
XAIR	41 Neutral	$14.76M	-0.16	-179.63%	―	147.74%	73.23%
ALUR	40 Underperform	$14.91M	―	―	―	-50.49%	39.93%

Allurion Technologies Corporate Events

Allurion Technologies Delays Q3 2025 Report Filing

Allurion Technologies, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending September 30, 2025. The primary reason for the delay is the need for additional time to complete the preparation and review of post-quarter-end items, which could not be accomplished without unreasonable effort or expense. The company expects to file the report within the five-day extension period provided by the notification. Financially, the company anticipates a significant change in its results, with expected total revenue of approximately $2.7 million, a decrease from $5.4 million in the same period last year. The notification includes forward-looking statements, cautioning investors about potential risks and uncertainties. The company is committed to maintaining compliance, as indicated by the signature of Brendan M. Gibbons, Chief Legal Officer.

The most recent analyst rating on (ALUR) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Allurion Technologies stock, see the ALUR Stock Forecast page.

Allurion Technologies Reports Q3 2025 Financial Results

Allurion Technologies, Inc., based in Natick, Massachusetts, is a leading company in the field of metabolically healthy weight loss, known for its innovative Allurion Program that includes the world’s first swallowable, procedureless gastric balloon for weight loss.

Allurion Technologies’ Earnings Call: Progress Amid Challenges

During the recent earnings call, Allurion Technologies, Inc. presented a mixed sentiment reflecting both achievements and challenges. The company celebrated significant strides in the FDA approval process and successful restructuring efforts that enhanced financial efficiencies. However, these positive developments were overshadowed by a notable decline in revenue and gross profit. Despite these challenges, Allurion’s strategic initiatives, such as debt restructuring and advancements in research and development, suggest a positive long-term outlook.

Allurion Technologies Secures $5M in New Funding

On November 11, 2025, Allurion Technologies entered into a securities purchase agreement to sell shares and warrants for approximately $5 million, aiming to strengthen its balance sheet. Concurrently, the company agreed to exchange outstanding debt for convertible preferred equity with RTW Investments, which will allow RTW to convert debt into Series B Preferred Stock, enhancing Allurion’s financial position. These strategic financial maneuvers are part of Allurion’s broader efforts to secure FDA approval for its products and position itself for long-term success in the weight-loss industry.

The most recent analyst rating on (ALUR) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Allurion Technologies stock, see the ALUR Stock Forecast page.

Allurion Technologies’ Earnings Call: Strategic Shift Amid Revenue Challenges

Allurion Technologies, Inc. Navigates Strategic Transition Amidst Revenue Challenges